NVN Liquidation Dividendos y recompras

Dividendo controles de criterios 0/6

NVN Liquidation no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-77,964,285.7%

Rendimiento de la recompra

Rendimiento total para el accionista	-77,964,285.7%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Jun 07

Novan Q2 2022 Earnings Preview

Aug 10

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Jul 19

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de NOVN.Q han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de NOVN.Q han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de NVN Liquidation vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de NOVN.Q con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (NOVN.Q)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.2%
Media de la industria (Pharmaceuticals)	2.4%
Analista de previsiones (NOVN.Q) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de NOVN.Q en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de NOVN.Q en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de NOVN.Q para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que NOVN.Q no ha comunicado ningún pago.

NVN Liquidation Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 14% to US$11.50

Consensus EPS estimates fall by 16%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 13% to US$12.67

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Q2 2022 Earnings Preview

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan shares under pressure after proposing capital raise

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan regains Nasdaq compliance for minimum bid price requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan EPS in-line, beats on revenue

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Price target lowered to US$2.75

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos